{"id":"W4396935701","doi":"10.1016/j.clcc.2024.05.002","title":"A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"Institute of Genetics; Genentech; Servier; Astellas Pharma; Eisai; Seagen; Sociedad Española de Oncología Médica; Mirati Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Celgene; Symphogen; Bristol-Myers Squibb; American Association for Cancer Research; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Olaparib; Durvalumab; Colorectal cancer; Oncology; Randomized controlled trial; Internal medicine; Open label; Cetuximab; Nivolumab; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001842499,0.001914183,0.002393011,0.0003681368,0.0003969403,0.001218538,0.0009142529,0.001466247,0.00660531],"category_scores_gemma":[0.001569103,0.0007661621,0.001262924,0.0003573017,0.001179653,0.00113769,0.0004433053,0.003008302,0.001068518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009207939,"about_ca_system_score_gemma":0.001340278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006908891,"about_ca_topic_score_gemma":0.001919708,"domain_scores_codex":[0.9993429,0.0003556349,0.00003571118,0.0001256396,0.00003912303,0.0001010972],"domain_scores_gemma":[0.9988977,0.0002403905,0.0002513293,0.0001023701,0.00005532378,0.000452856],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9789842,0.008029916,0.0006350363,0.0002093129,0.0004648489,0.0000373963,0.00003866047,0.0002511867,0.002545895,0.00008201988,0.0005299453,0.008191552],"study_design_scores_gemma":[0.958134,0.04009394,0.0007477594,0.000009220519,0.0001140972,0.00002743029,0.00001206741,0.0002343318,0.0002051968,0.0000795958,0.0003360147,0.000006276955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883335,0.002606226,0.0005975073,0.0006915145,0.00046492,0.004482119,0.001071788,0.00007950832,0.001672991],"genre_scores_gemma":[0.9839609,0.001863215,0.001654532,0.001462625,0.0004178096,0.006060922,0.001625259,0.00002299132,0.002931855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00660531,"threshold_uncertainty_score":0.02209693,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05931110347040201,"score_gpt":0.4103780571519678,"score_spread":0.3510669536815658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}